Hepatitis C

In the United States, an estimated 50-90 percent of injection drug users living with HIV are co-infected with HCV. Driven by rising rates of injection drug use, the incidence of hepatitis C in the United States has tripled in the last five years. The amfAR policy office advocates for increased access to prevention and treatment services for people living with, or at risk for, hepatitis C. policy office maintains a database of epidemiological, policy, and funding data on opioid use, HIV, and hepatitis C.

New Study Suggests Most Substance Abuse Facilities Don’t Test for HIV

Toward an Effective Strategy to Combat HIV, Hepatitis C and the Opioid Epidemic: Recommendations for Policy Makers

Issue Brief: The Case for Supervised Consumption Services

Preventing HIV and Hepatitis Infections Among People Who Inject Drugs: Leveraging an Indiana Outbreak Response to Break the Impasse